（文章来源：证券日报） 证券日报网讯易明医药11月24日在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东数 为18924户。 ...

Core Insights - Yiming Pharmaceutical stated that as of October 31, 2025, the number of shareholders will be 21,147 [2] Company Summary - Yiming Pharmaceutical is actively engaging with investors through interactive platforms [2] - The company is projecting a specific number of shareholders for a future date, indicating a focus on shareholder engagement and growth [2]

Core Insights - 易明医药 is a pharmaceutical company established in December 2007, focusing on the research, production, and sales of chemical drugs and traditional Chinese medicine, with strengths in generic drugs [1] Financial Performance - In Q3 2025, 易明医药 reported revenue of 489 million yuan, ranking 81st among 110 companies in the industry, while the industry leader, 华东医药, achieved revenue of 32.664 billion yuan [2] - The company's net profit for the same period was 81.76 million yuan, placing it 55th in the industry, with the top performer, 恒瑞医药, reporting a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, 易明医药's debt-to-asset ratio was 24.24%, an increase from 22.52% year-on-year, which is below the industry average of 35.26% [3] - The company's gross profit margin for Q3 2025 was 82.15%, up from 67.05% year-on-year, exceeding the industry average of 57.17% [3] Management Compensation - The total compensation for the general manager was 681,600 yuan in 2024, a decrease of 23,400 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.58% to 19,400, while the average number of circulating A-shares held per shareholder increased by 9.38% to 8,968.79 [5]

Core Insights - Yiming Pharmaceutical (002826.SZ) reported its Q3 2025 results, highlighting significant institutional investment growth [1] Institutional Holdings - As of October 28, 2025, five institutional investors disclosed holdings in Yiming Pharmaceutical, totaling 48.1693 million shares, which represents 25.26% of the company's total share capital [1] - The institutional holding percentage increased by 24.33 percentage points compared to the previous quarter [1] Public Fund Activity - One new public fund disclosed its holdings this quarter, namely Wanji Zhongzheng 2000 Index Enhanced A [1] - Eleven public funds were not disclosed in this quarter compared to the previous one, including notable funds such as CITIC Securities Quantitative Selection A and Jianxin Zhongzheng 500 Index Enhanced A [1]

Core Viewpoint - The company, Xizang Yiming Xiya Pharmaceutical Technology Co., Ltd., has released its third-quarter financial report for 2025, ensuring the accuracy and completeness of the information disclosed [1][2]. Financial Data Summary - The company reported a 30.35% decrease in cash and cash equivalents compared to the beginning of the period, primarily due to investments in financial products [5]. - Trading financial assets increased by 280 million yuan, attributed to the purchase of short-term financial products [5]. - Accounts receivable notes decreased by 94.26%, reflecting the maturity and settlement of receivables [5]. - Prepayments increased by 3.75 million yuan, mainly due to payments made to suppliers and for engineering projects [5]. - Construction in progress doubled compared to the beginning of the period, due to payments for production line renovations [5]. - Accounts payable grew by 34.33%, linked to increased procurement and promotional service fees [5]. - Contract liabilities decreased by 57.03%, indicating a reduction in advance payments received [5]. - Tax liabilities increased by 13.06 million yuan, reflecting higher corporate income tax and VAT provisions [5]. - Other payables rose by 90.17%, primarily due to the recognition of obligations related to a stock incentive plan [5]. - Operating costs decreased by 48.35% year-on-year, due to the termination of third-party product collaborations [5]. - Financial expenses increased by 78.55%, driven by higher interest expenses from increased short-term borrowings [5]. - Investment income rose by 803,100 yuan, attributed to increased returns from financial product investments [5]. - Net cash flow from operating activities grew by 31.41%, due to increased sales and government subsidies [5]. Shareholder Information - As of the reporting period, the company’s shares held by the repurchase account amounted to 3,403,800 shares, representing 1.79% of the total share capital [7]. - A significant change in control occurred when Beijing Fuhai Enterprise Management Partnership acquired 23.00% of the company's shares from the previous controlling shareholder [7][8]. Board Meeting and Governance - The fourth board meeting was held on October 27, 2025, with all directors present, and the meeting complied with relevant laws and regulations [10][11]. - The board approved the third-quarter report, confirming that it accurately reflects the company's situation without any misleading statements [11][12].

Major Events - *ST Zhengping's stock will be suspended for investigation starting October 29, 2025, due to a significant price increase of 152.42% from September 1 to October 28, 2025, with 21 days of trading halts and 5 instances of abnormal trading fluctuations [2] - Gongjin Co. announced that its major shareholder is planning a share transfer that may lead to a change in control, resulting in the stock being suspended from October 27, 2025, for up to 3 trading days [2] - Jiuquan Technology's wholly-owned subsidiary plans to invest 150 million yuan in establishing an industrial fund focused on chips and integrated circuits [2] Company Announcements - YN Holdings decided to terminate investment in 17 distributed photovoltaic projects originally planned for a total investment of 1.197 billion yuan due to changes in market conditions [3] - Awan New Materials announced a one-day stock suspension on October 29, 2025, due to a tender offer from Shanghai Zhiyuan Hengyue Technology Partnership, aiming to acquire 149,243,840 shares at 7.78 yuan per share [4] - Dahua Intelligent clarified that it currently has no business related to quantum technology despite market speculation [5] Financial Performance - Ganfeng Lithium reported a net profit of 557 million yuan for Q3 2025, a year-on-year increase of 364.02%, with revenues of 6.249 billion yuan, up 44.10% [6] - Light Media's net profit for Q3 2025 reached 1.06 billion yuan, a 993.71% increase, with revenues of 374 million yuan, up 247.54% [6] - Hainan Airport reported a net profit of 64.35 million yuan for the first three quarters of 2025, a decline of 69.77% [7] - Su Li Co. achieved a net profit of 59.42 million yuan in Q3 2025, a 2750% increase, with revenues of 762 million yuan, up 26% [7] - Yutong Bus reported a net profit of 1.357 billion yuan for Q3 2025, a 78.98% increase, with revenues of 10.237 billion yuan, up 32.27% [9] Share Buybacks - Haida Group plans to repurchase shares worth between 1 billion to 1.6 billion yuan for capital reduction and employee stock ownership plans, with a maximum price of 62 yuan per share [20] - Liyuan Information intends to repurchase shares totaling 20 million to 30 million yuan, with a maximum price of 15 yuan per share [21] Major Contracts - Baiao Intelligent won a project worth 97.22 million yuan from a large state-owned company [22] - Guangdong Construction signed a construction contract worth 1.924 billion yuan for a project in Guangzhou, which will enhance its business scale and profitability [22] - Guangqi Technology's subsidiary signed contracts for mass production of metamaterials worth a total of 215 million yuan [23]

Core Insights - The company reported a revenue of 177,538,389.36 yuan for Q3 2025, representing a year-on-year growth of 10.37% [1] - The net profit attributable to shareholders reached 44,206,127.26 yuan, showing a significant year-on-year increase of 1934.12% [1] Financial Performance - Revenue for Q3 2025: 177.54 million yuan, up 10.37% year-on-year [1] - Net profit for Q3 2025: 44.21 million yuan, up 1934.12% year-on-year [1]

Core Viewpoint - The news summarizes important announcements from various companies, highlighting stock suspensions, significant profit growth, and major contracts signed, which may present investment opportunities and insights into market trends [1][2]. Stock Suspensions - *ST Zhengping announced that its stock will be suspended from trading starting October 29, 2025, due to a significant price increase of 152.42% from September 1 to October 28, 2025, and abnormal trading fluctuations [3]. - Gongjin Co. announced a stock suspension starting October 27, 2025, due to the major shareholder planning a share transfer that may lead to a change in control [4]. Investment Activities - Juyuan Technology's subsidiary plans to invest 150 million yuan in establishing an industrial fund focused on chips, integrated circuits, and other high-growth sectors [5]. - YN Holdings decided to terminate investments in 17 distributed photovoltaic projects, originally planned to cost 1.197 billion yuan, due to changes in market conditions [6]. Earnings Reports - Suliy Co. reported a 2750% increase in net profit for Q3 2025, with revenue of 762 million yuan, up 26% year-on-year [8]. - Xianda Co. reported a net profit of 59.85 million yuan for Q3 2025, a 5447% increase, despite a 5.59% decline in revenue [9]. - Yutong Bus reported a net profit of 1.357 billion yuan for Q3 2025, a 78.98% increase, with revenue of 10.237 billion yuan, up 32.27% [10]. - Juxin Technology reported a net profit of 60.27 million yuan for Q3 2025, a 101.09% increase, with revenue of 273 million yuan, up 46.64% [11]. - Guanghong Technology reported a net profit of 99.61 million yuan for Q3 2025, a 99.68% increase, with revenue of 2.937 billion yuan, up 57.46% [12]. - Mingzhi Electric reported a net profit of 22.88 million yuan for Q3 2025, a 215.97% increase, with revenue of 729 million yuan, up 28.98% [13]. - Zhongwei Semiconductor reported a net profit of 65.82 million yuan for Q3 2025, a 3.66% decrease, with revenue of 269 million yuan, up 21.88% [14]. - Yiming Pharmaceutical reported a net profit of 44.21 million yuan for Q3 2025, a 1934.12% increase, with revenue of 178 million yuan, up 10.37% [15]. - Weilan Bio reported a net profit of 35.06 million yuan for Q3 2025, a 205.02% increase, with revenue of 364 million yuan, up 8.09% [16]. - Baiyunshan reported a net profit of 794 million yuan for Q3 2025, a 30.28% increase, with revenue of 19.771 billion yuan, up 9.74% [17]. - Giant Network reported a net profit of 640 million yuan for Q3 2025, an 81.19% increase, with revenue of 1.706 billion yuan, up 115.63% [18]. Share Buybacks - Haida Group announced a plan to repurchase shares worth between 1 billion and 1.6 billion yuan, aimed at reducing registered capital and implementing employee stock ownership plans [20]. Major Contracts - Bai'ao Intelligent announced it won a project worth 97.22 million yuan from a large state-owned company [22]. - Guangdong Construction signed a construction contract worth 1.924 billion yuan for a project in Guangzhou, with a duration of 1365 days [23][24].

Core Insights - The company reported a third-quarter revenue of 178 million, representing a year-on-year increase of 10.37% [1] - The net profit for the third quarter was 44.21 million, showing a significant year-on-year growth of 1934.12% [1] - For the first three quarters, the total revenue was 489 million, reflecting a year-on-year decline of 4.65% [1] - The net profit for the first three quarters reached 81.76 million, which is a year-on-year increase of 95.52% [1]

二、董事会会议审议情况 1、审议通过了《关于公司2025年第三季度报告的议案》； 董事会在全面了解和审核公司 2025 年第三季度报告后一致认为：公司 2025 年第三季度报告的编制和审核程序符合法律、行政法规和中国证监会的规定，报 告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏。 证券代码：002826 证券简称：易明医药 公告编号：2025-065 西藏易明西雅医药科技股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"）第 四届董事会第二次会议于 2025 年 10 月 27 日在公司会议室以现场与通讯相结合 的方式召开。本次会议于 2025 年 10 月 17 日以电子邮件方式通知了全体董事。 本次会议应到董事 7 人，实到董事 7 人。高级管理人员列席了会议。会议 由董事长付丽华女士召集和主持，董事会秘书李前进女士出席并记录了本次会议。 本次会议的召集、召开和表决程序符合《中华人民 ...